Craft

Intersect ENT

Stock Price

$28.2

2022-05-13

Market Capitalization

$945 M

2022-05-13

Revenue

$106.7 M

FY, 2021

Intersect ENT Summary

Company Summary

Overview
Intersect ENT is an ear, nose, and throat medical technology company. It offers steroid releasing implants that are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. These products include the PROPEL family of products and the SINUVA sinus implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers, with applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician-administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps.
Type
Public
Status
Active
Founded
2003
HQ
Menlo Park, CA, US | view all locations
Website
http://www.intersectent.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Thomas A. West

    Thomas A. West, President and Chief Executive Officer, Director

  • Patrick Broderick

    Patrick Broderick, Executive Vice President, General Counsel and Corporate Secretary

  • Reyna Fernandez

    Reyna Fernandez, Chief Human Resources Officer

  • Rich Kaufman

    Rich Kaufman, Chief Operating Officer & Senior Vice President R&D

Operating MetricsView all

Patients

150K

FY, 2016

Patents Issued

77

FY, 2016

Facilities

1

FY, 2016

LocationsView all

1 location detected

  • Menlo Park, CA HQ

    United States

    1555 Adams Dr

Intersect ENT Financials

Summary Financials

Revenue (Q1, 2022)
$21.6M
Gross profit (Q1, 2022)
$13.9M
Net income (Q1, 2022)
($28.8M)
Cash (Q1, 2022)
$25.6M
EBIT (Q1, 2022)
($26.7M)

Footer menu